Structure:1 tablet contains 0.1 mg of reserpine, digidralazina sulfate 10 mg. Tablets of 250 and 500 pieces in packaging. - Pharmacological action. Combined antihypertensive drugs. The drug contains two active ingredients complementing the hypotensive effect of each other: sympatholytic reserpine and myotropic antispasmodic digidralazin. Adelfan causes a gradual and sustained reduction in blood pressure.
The action of reserpine is associated with depletion of catecholamines in postganglionic sympathetic nerve endings, which leads to a reduction of cardiac and total peripheral resistance. Moreover, reserpine has a central effect, causes sedation. Digidralazina sulfate reduces the tone of smooth muscles of blood vessels (mostly arterioles), reduces peripheral vascular resistance. Reduces vascular resistance in the brain and kidneys. If you are using does not appear Adelfan characteristic digidralazina reflex tachycardia, since it prevented reserpine.
Dosing: Drug should be individualized. The average dose is 1 tablet 3 times a day. If necessary, the dose can be temporarily increased to 2 tablets 3 times a day.
Side effects: Subject to the recommended dosage regimen side effects are rare. There are - fatigue, weakness, feeling laid-surface of the nose.
In predisposed patients, especially for prolonged use at high doses, may cause depression.
Contraindications: High sensitivity to any of the components of the drug, marked depression, Parkinson's disease, epilepsy, electroconvulsive therapy, pheochromocytoma, concomitant treatment with MAO inhibitors, gastric ulcer and duodenal ulcer in acute phase, ulcerative colitis, marked tachycardia, severe forms of angina and arrhythmia; recent history of myocardial infarction, severe forms of renal failure, anuria, pronounced liver damage, pregnancy (III trimester), lactation.
Special instructions: Be particularly careful in the appointment of the drug to patients with heart failure, coronary and cerebral atherosclerosis, history of myocardial infarction, peptic ulcer, erosive gastritis, depression.
Designate caution Adelfan those professions that require special attention, rapid mental and motor responses.
If signs of depression medication should be discontinued. In the case of allergies (sometimes with e fever and rash), the drug should be immediately abolished.
MAO inhibitors should be discontinued no later than 2 weeks before the start of treatment with Adelfan.
The drug should be discontinued 7 days prior to electroconvulsive therapy.
The drug should be discontinued several days before elective surgery to avoid excessive loss of blood pressure during anesthesia. In case of emergency surgery patients showed a preliminary introduction of sufficient doses of atropine to prevent severe bradycardia.
Patients receiving Adelfan, caution should be exercised when applying the eye drops, nose drops and other medications, which include adrenomimeticheskim substance.
During pregnancy (v! and I! trimesters) Appointment Adelfan possible only in cases of extreme necessity. - Overdose. If poisoning associated with overdose Adelfan, there may be symptoms such as rolovnaya pain, dizziness, drowsiness, confusion, extrapyramidal disorders, convulsions, paresthesia, miosis, coma. May also experience nausea, vomiting, diarrhea. Also marked tachycardia, hypotension, syncope, and sometimes - myocardial ischemia, cardiac arrhythmia, respiratory depression. - Treatment. Induce vomiting or gastric lavage, give activated charcoal. In the presence of hypotension the patient should be put; shows the introduction of plasma substitutes and, if necessary, injection of adrenalin. In the case of diarrhea is shown introducing anticholinergics. In the case of seizures showed a slow intravenous diazepam. In the case of pronounced respiratory depression shows an artificial ventilation. The duration of observation of the patient is not less than 72 hours - Drug Interactions. Hypotensive effect Adelfan enhanced by simultaneous administration of other antihypertensive drugs